- Home
- VEL vs NUVB Comparison
VEL vs NUVB Comparison
Compare VEL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- NUVB
- Stock Information
- Founded
- VEL 2004
- NUVB 2018
- Country
- VEL United States
- NUVB United States
- Employees
- VEL N/A
- NUVB N/A
- Industry
- VEL Finance: Consumer Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- NUVB Health Care
- Exchange
- VEL Nasdaq
- NUVB Nasdaq
- Market Cap
- VEL 680.6M
- NUVB 679.9M
- IPO Year
- VEL 2020
- NUVB N/A
- Fundamental
- Price
- VEL $17.30
- NUVB $2.55
- Analyst Decision
- VEL Buy
- NUVB Strong Buy
- Analyst Count
- VEL 5
- NUVB 6
- Target Price
- VEL $21.20
- NUVB $7.83
- AVG Volume (30 Days)
- VEL 82.5K
- NUVB 5.5M
- Earning Date
- VEL 08-07-2025
- NUVB 08-04-2025
- Dividend Yield
- VEL N/A
- NUVB N/A
- EPS Growth
- VEL 14.80
- NUVB N/A
- EPS
- VEL 1.94
- NUVB N/A
- Revenue
- VEL $177,987,000.00
- NUVB $10,957,000.00
- Revenue This Year
- VEL N/A
- NUVB $98.78
- Revenue Next Year
- VEL $32.82
- NUVB $489.71
- P/E Ratio
- VEL $8.91
- NUVB N/A
- Revenue Growth
- VEL 39.36
- NUVB N/A
- 52 Week Low
- VEL $16.12
- NUVB $1.54
- 52 Week High
- VEL $20.98
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- VEL 37.88
- NUVB 65.10
- Support Level
- VEL $17.40
- NUVB $2.46
- Resistance Level
- VEL $17.99
- NUVB $2.62
- Average True Range (ATR)
- VEL 0.35
- NUVB 0.16
- MACD
- VEL -0.10
- NUVB 0.04
- Stochastic Oscillator
- VEL 3.34
- NUVB 69.29
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).